Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Open Orphan Plc LSE:ORPH London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.00 3.45% 30.00 29.00 30.00 30.25 29.25 29.25 2,328,771 16:35:25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3.3 -5.6 -3.4 - 200

Open Orphan Share Discussion Threads

Showing 10051 to 10072 of 14025 messages
Chat Pages: Latest  405  404  403  402  401  400  399  398  397  396  395  394  Older
DateSubjectAuthorDiscuss
28/11/2020
07:38
Might be trades from previous days of the week.
little minx
27/11/2020
22:54
Can someone please explain to me, how come many of the larger trades declared after the market has closed, are at a price less than the lowest bid for the day. If you buy in bulk- does it warrant a discount ?I have level 2.
klosters65
27/11/2020
18:47
Looking like that's closed slightly above the 'pennant'. Early days yet but it's deffo above. free stock charts from uk.advfn.com
owenski
27/11/2020
16:21
Global regulators urge continuation of COVID-19 vaccine trials for longer-term safety and efficacy EMA has endorsed a statement by the International Coalition of Medicines Regulatory Authorities (ICMRA) that urges all stakeholders, including vaccines researchers and investigators, academia, regulators and the pharmaceutical industry, to continue COVID-19 vaccine trials beyond the time when the pre-defined cases of COVID-19 disease for final analysis in a trial have been reached. This can provide important additional and more precise information on longer-term safety and efficacy of a vaccine against COVID-19. ‘The work of ICMRA in streamlining regulatory requirements for vaccines through global cooperation has supported the rapid development of COVID-19 vaccines,’ said Emer Cooke, Chair of ICMRA and EMA’s Executive Director. ‘Vaccines will be a key component in overcoming COVID-19, and we must ensure that robust and convincing evidence is being generated to enable the continuous assessment of their benefits and risks.’ https://www.ema.europa.eu/en/news/global-regulators-urge-continuation-covid-19-vaccine-trials-longer-term-safety-efficacy-follow
trader_3
27/11/2020
15:21
Hoping for a bit more today. Got a bit excited with the early break but should know by now its never done until the close. As we are not at the close yet, it may still happen, if not we are still within the pennant, awaiting a significant move IMHO.
m5
27/11/2020
13:33
Yup NTS agree we were going down a dead end on the ethics discussion so leave it. Good to have another poster with different perspectives.
pogue
27/11/2020
13:10
M5 - cheers
nickthe saint
27/11/2020
12:57
This breakout goes according to plan, you might not have to wait that long.
m5
27/11/2020
12:26
It would be nice to see the share price "bogged down" closer to 50p!! Huge question marks around these vaccines currently - should be playing into our hands.
felchandbart
27/11/2020
11:57
NTS, welcome on board. All discussions welcome, but I think your point about getting bogged down is a very fair one.
m5
27/11/2020
11:45
Morning all, Trout - good to hear re last years Pneumo Vax :-) Marvel - Thank you for a warm welcome. Pogue - thanks for your info but I dont think I stated that Challenge studies were the only place that the Hippocratic Oath might come in to play. If thats how you read it sorry for any confusion. What I was trying to clarify is that there IS Def an ethical debate about Challenge Studies - Cathal even says that too on the odd occassion. The ethical debate centres around the "do no harm". It is a debate that I lean on the side of "yes challenge studies in controlled settings should be utilised". Am happy to leave that topic now as I had intended to clarify some of the situatiuon for those whoi maybe havent had the incite that I and others have. Lets try and move the discussion on from that. I liken vaccine development to injecting people with Strawberry milkshake. In its self it isnt a disease or virus but it might do some harm to some people, but you would inject them in a trial if you thought it might prevent alcoholism. If you injected them with alcohol (which is poisonous in sufficient quantities to all of us) but at a small level of ml in the hope that it cures alcoholism then in theory you are doing a bit of potential harm. If you inject someone with Covid you def know you are doing some harm (albeit perhaps ina a mild form). I have a lot to contribute to the debate but I dont want any of us to get bogged down in minute detail - not good for our mental well being. Pierre - you are correct when you refer to the intention to do harm. Best regards to all. NTS
nickthe saint
27/11/2020
11:39
hVIVO Consortium & Leiden University 'hVIVO is leading a consortium, on behalf of HIC-Vac, an international network of researchers who are developing human infection challenge (HIC) studies to accelerate the development of vaccines against pathogens, and the Wellcome Trust, to generate regulatory style guidelines on the manufacture of human challenge agents for subsequent use in controlled human infection studies (CHIM).' Meta Roestenberg Organisation Lead Leiden University Medical Center, Department of Parasitology Angela Van Diepen Scientific Adviser Role Leiden University Medical Center, Department of Parasitology hxxps://hvivo.com/aboutus/clinical-trial-consortium/
trader_3
27/11/2020
10:39
Like this price action this morning. Its playing out so far. I think we could be in for a very decent move. IMHO,DYOR.
m5
27/11/2020
10:29
Four reasons why we need multiple vaccines for Covid-19 hxxps://wellcome.org/news/four-reasons-why-we-need-multiple-vaccines-covid-19?utm_source=twitter&;utm_medium=o-wellcome Apologies if previously posted.
trader_3
27/11/2020
10:23
Trader and m5 - very interesting. Thanks. Looks like we are on in Jan, dispelling some lingering doubts by some perhaps. hTTps://hansard.parliament.uk/commons/2020-11-26/debates/20112638000005/DepartmentalContingentLiabilityNotificationHumanChallengeProject
wassapper
27/11/2020
10:20
pogue - I'm not sure that's correct - about upping the dose until it does harm. They do pre-clinical (i.e. animal) studies for that, where they do deliberately give multiples of the dose they might give in human trials to find out when they start getting adverse events. By the time they start on human trials, phase 1, they have a good idea from the animal models what an effective dose is and how high they can reasonably take the dose before they might start to see an unacceptable level of, or unacceptably serious, adverse events. My understanding of Phase 1 trials is that at that point they are setting out to confirm in human trials that the range of doses they think is safe from the pre-clinical trials actually is safe in humans. Regulators are unlikely to give approval to human trials, I would have thought, if the intention is to use "unsafe" doses.
1gw
27/11/2020
10:02
Pierre giving someone something until it causes harm is what they do in Phase 1 trials that is the intention find the safe limit to do that you have to cross it which is by definition doing harm. Pointless debate we are not getting anywhere useful I started by challenging Nick on his assumptions but makes no difference to ORPH.
pogue
27/11/2020
10:00
James, 25ish needs to rise about 25% to get to recent highs.
pierre oreilly
27/11/2020
09:56
P, the oath isn't about outcomes, it's about intentions. Lots of things drs do harm and even kill people, but the intention it to help them.
pierre oreilly
27/11/2020
09:55
Most probably more dangerous crossing the road statically than having a mild dose jab
malcolmmm
27/11/2020
09:52
discojames I was trying to point out that challenge studies are no different to phase 1 tests for drugs side effects. I am not arguing against challenge studies just debating with Nick who says challenge studies are the only tests that contradict the do no harm ethos of the medical profession. I am all for challenge studies if volunteers are willing and are advised of the risks then they are worthy of praise, and payment, for trying to help the common good just like soldiers who volunteer to fight and possibly die for their country. Pierre you made me think for a second there, Challenge studies are allowed in the UK as you say but imagine they weren't then ORPH could easily decamp to another country that did. Very worst case I am sure the Chinese would welcome us with open arms though I imagine Belgium would be handier for CF. Edit Troutisout I am not taking it too literally, side effects of drugs can go from zero to fatal quite rapidly I image, one minute you are fine next your are not how severe is the unknown but a trigger for something to shutdown may just be a slight increase. The reason of phase 1 trails is to test what dosage causes side effects not if they cause side effects, subtle difference.
pogue
27/11/2020
09:50
Just got quoted 25.11p to sell a little over 100,000
666james
Chat Pages: Latest  405  404  403  402  401  400  399  398  397  396  395  394  Older
ADVFN Advertorial
Your Recent History
LSE
ORPH
Open Orpha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210224 21:38:42